Iktos opens a subsidiary in Japan and entrusts its management to Hideyoshi Fuji
Retrieved on:
Wednesday, February 14, 2024
Molecule, Urology, Pharmacy, Doctor of Philosophy, AI, Yann, Saas, Generative, Drug design, Drug discovery, RIKEN, Kissei, Retrosynthetic analysis, Software as a service, Astellas Pharma, Artificial intelligence, Computational chemistry, Toyotomi Hideyoshi, Ono Pharmaceutical, Pharmaceutical industry
Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
Key Points:
- Paris (France) and Tokyo (Japan), February 14, 2024 – Iktos, a company specialized in Artificial Intelligence for new drug design, announces the opening of Iktos K.K., its new subsidiary in Japan.
- Hideyoshi Fuji has been appointed Representative Director of Iktos K.K., and Vice-President, Japan Business Development and Operations.
- Hideyoshi, 42, spent 13 years at Astellas Pharma Inc. (2009-2021) as an expert in computational chemistry and chemoinformatics.
- After his career with Astellas Pharma, Hideyoshi became an entrepreneur in 2022 and supported business development and marketing efforts in Japan for overseas software companies.